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The issue of protection and promotion of physical health 
in persons with severe mental illness is emerging as one of 
great public health and ethical relevance worldwide. If we 
are really concerned about the quality of life of our patients 
with severe mental disorders and with the protection of their 
civil rights, we cannot ignore that physical health is a crucial 
dimension of quality of life in these persons, and that the 
access to a physical health care of the same quality as that 
available to the rest of the population is a basic right of these 
persons as human beings and as citizens. 
As reviewed by De Hert et al in this issue (1), there is now 
an extensive research evidence that: a) the prevalence of 
many physical diseases is higher in persons with severe men-
tal illness than in the general population (2); b) the gap be-
tween these persons and the rest of the population concern-
ing the prevalence of some of these diseases (notably, type 2 
diabetes mellitus) has been increasing in the past few de-
cades (3); c) the co-existence of one or more physical dis-
eases has a significant impact on many quality of life and 
psychopathological variables in persons with severe mental 
illness (4); d) mortality due to physical diseases is higher in 
persons with severe mental illness than in the general popu-
lation (5), and the gap concerning mortality due to some 
diseases (in particular, ischaemic heart disease) has been in-
creasing in recent decades (6); e) the access to physical 
health care of persons with severe mental illness is reduced 
compared to the general population (6); f) the quality of 
physical health care received by persons with severe mental 
illness is poorer than the general population: recent data 
about mortality due to post-operative respiratory failure (ad-
justed odds ratio, OR=8.85) and post-operative sepsis (ad-
justed OR=7.14) in persons with schizophrenia are striking 
in this respect (7).
In order to address this situation, several lines of action 
can be identified. Raising awareness of the problem among 
mental health professionals, primary care practitioners, pa-
tients and their families is obviously a first priority. The avail-
able research information about the increased morbidity 
and mortality due to physical diseases in people with severe 
mental disorders should be much better disseminated.
Education and training of mental health professionals 
and primary care providers is one more essential step. Men-
tal health professionals should be trained to perform at least 
basic medical tasks. They should be educated about the im-
portance of recognizing physical illness in people with se-
vere mental disorders. They should be encouraged to famil-
iarize themselves with the most common reasons for under-
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diagnosis or misdiagnosis of physical illness in their patients 
(8). On the other hand, primary care providers should over-
come their reluctance to treat persons with severe mental 
illness. They should learn effective ways to interact and com-
municate with these persons: it is not so much an issue of 
knowledge and skills; it is mostly an issue of attitudes. 
Another essential step is the development of an appropri-
ate integration between mental health and physical health 
care. There is some debate in the literature about who should 
monitor physical health in people with severe mental illness. 
What really matters, however, is that there is always some-
body who cares: every patient should have a professional 
who is identified as responsible for his/her physical health 
care. On the other hand, mental health services should be 
able to provide at least a standard routine assessment of their 
patients, in order to identify or suspect the presence of phys-
ical health problems. Currently available guidelines about 
the choice of antipsychotic medication in the individual pa-
tient and the management of patients receiving antipsychot-
ics should be known and applied by all mental health ser-
vices. Mental health professionals should encourage patients 
to monitor and chart their own weight and should sensitize 
patients and their caregivers to the health risk associated 
with excess weight. Dietary and exercise programs should be 
an essential part of what mental health services provide. 
Finally, further research in this area is badly needed. Phys-
ical illnesses should not be always regarded as confounding 
variables in studies dealing with severe mental disorders. 
They should be studied by specific research protocols, so 
that the interaction between mental disorders and the vari-
ous physical diseases – in men as well as in women; in young 
people as well as in the elderly; in inpatients as well as in 
outpatients – can be better understood. This could also fa-
cilitate the development of closer working relationships be-
tween physical and mental health professionals.
The WPA will implement during this triennium an inter-
national programme on the protection and promotion of 
physical health in persons with severe mental illness, in col-
laboration with other international and national medical 
associations and with some organizations of users and fam-
ilies. One of the components of the project will be the de-
velopment of an educational module to be used in training 
of residents in psychiatry, dealing with physical diseases 
and access to health care services in persons with schizo-
phrenia. 
The promotion of physical health care in people with se-
vere mental illness is today a key issue in our field. If we do 
001-002.indd   1 2-02-2009   12:43:44
2 World Psychiatry 8:1 - February 2009
not regard it as a priority, we will not be able to state con-
vincingly that a better quality of life and the protection of the 
civil rights of our patients is really what we strive toward.
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People with severe mental illnesses (SMI), such as schiz-
ophrenia, have a reduced life expectancy compared to the 
general population (1-13). They have a 2-3 fold increased 
risk of dying, and this mortality gap associated with mental 
illness compared to the general population has widened in 
recent decades (13). People with severe mental illness have 
nearly twice the normal risk of dying from cardiovascular 
disease (CVD) (1-13).
In the psychiatric community, this has led in recent years 
to a growing concern about physical illness in people with 
SMI, specifically CVD risk (14-24). People with SMI are 
more likely to be overweight, to smoke and to have hyper- 
glycaemia/diabetes, hypertension and dyslipidaemia (Table 
1). With an overall increased risk of somatic comorbidities, 
patients with schizophrenia have poorer access and quality 
of physical health care (7,25-27).
In part these cardio-metabolic risk factors are attributable 
to unhealthy lifestyle, including poor diet and sedentary be-
haviour. But over recent years it has become apparent that 
antipsychotic agents (AP) can have a negative impact on 
some of the modifiable risk factors (7,14,15-42) (Table 2). 
Part of this negative impact can be explained by the liability 
of some antipsychotics to induce significant weight gain. A 
recent study indicates that these metabolic changes are dose 
independent (42).
Metabolic syndrome (MetS) brings together a series of 
abnormal clinical and metabolic findings which are predic-
tive of CVD risk, though there is continuing debate around 
the use of the term (44-50). The causes of MetS are not fully 
understood, but there is a central role of visceral adiposity 
and insulin resistance. The most commonly used definitions 
for the MetS are the Adult Treatment Panel III (ATP III) of 
the National Cholesterol Education Program (NCEP) (46), 
and the adapted ATP III-A proposed by the American Heart 
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Association following the American Diabetes Association 
lowering of the threshold for impaired fasting glucose to 100 
mg/dl (45,47). A more recent definition, by the Internation-
al Diabetes Federation (45,49), stressed the importance of 
waist circumference, using both more stringent and ethnic/
race specific criteria (Table 3). 
In the general population, the presence of MetS is a strong 
predictor of CVD, CVD mortality and diabetes (50-58).
Table 1  Estimated prevalence and relative risk (RR) of modifiable 
cardiovascular disease risk factors in schizophrenia and bipolar 
disorder compared to the general population (from 16)
Estimated prevalence, % (RR) 
Modifiable risk factors Schizophrenia Bipolar disorder
Obesity
Smoking
Diabetes
Hypertension
Dyslipidaemia
Metabolic syndrome
45-55 (1.5-2)
50-80 (2-3)
10-15 (2)
19-58 (2-3)
25-69 (≤5)
37-63 (2-3)
21-49 (1-2)
54-68 (2-3)
8-17 (1.5-2)
35-61 (2-3)
23-38 (≤3)
30-49 (1.5-2)
Table 2  Second generation antipsychotic agents and metabolic ab-
normalities (14,41,107-109)
Antipsychotic Weight gain Risk for diabetes Worsening  
lipid profile
Clozapine
Olanzapine
Risperidone
Quetiapine
Aripiprazole
Ziprasidone
Amisulpride
+++
+++
++
++
6
6
6
+
+
?
?
No report
No report
No report
+
+
?
?
No report
No report
No report
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A joint statement from the American Diabetes Associa-
tion and the European Association for the Study of Diabetes 
concluded recently that the metabolic syndrome has been 
imprecisely defined, there is a lack of certainty regarding its 
pathogenesis, and there is considerable doubt regarding its 
value as a CVD risk marker. They recommended that, until 
further research has been carried out, clinicians should eval-
uate and treat all CVD risk factors whether or not patients 
meet the criteria for diagnosis of the MetS (59,60).
The concept of MetS has found its way into the psychiatric 
literature, helping psychiatric clinicians to focus more on 
CVD risk in patients treated with antipsychotics (34,35,61).
We conducted a systematic review on the prevalence and 
incidence of metabolic syndrome in patients suffering from 
schizophrenia. A literature search for relevant articles was 
carried out in two steps. First, articles published until August 
1, 2008 were identified by PubMed search, using metabolic 
syndrome, antipsychotic(s), psychotic disorder and schizo-
phrenia as key words. Second, a hand search was conducted 
based on the bibliography of the identified articles. 
Since the first paper on MetS in patients with schizophre-
nia published in 2003, more than 30 studies have become 
available. Prevalence and incidence studies using different 
MetS criteria are shown in Tables 4 and 5 (62-99). Studies 
in different ethnic groups consistently show elevated preva-
lences of MetS in patients with schizophrenia. If population 
comparison data are available, the rates of MetS are 2 to 3 
fold higher in patients. In studies where a comparison was 
possible between antipsychotic medications, a differential 
relative metabolic risk between agents was confirmed.
In the largest study, the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE), approximately one 
third of patients met NCEP criteria for metabolic syndrome 
at baseline (82,83). A troubling finding was that 88% of pa-
tients with dyslipidaemia were not receiving treatment, as 
were 62% of the hypertensive patients and 38% of those 
with diabetes (100). Some antipsychotic agents were associ-
ated with more significant adverse effects on weight, lipids, 
and glucose metabolism than others (25,41,84).
A large Belgian study found similar rates of MetS, which 
were 2 to 3 fold higher than in an age-adjusted population 
sample (71,72). The prevalence of diabetes per age-band was 
4-5 times higher in schizophrenia patients than in the gen-
eral population.
In a recent study of metabolic syndrome in patients diag-
nosed with schizophrenia in 2000-2006 compared to 1984-
1995, those started on second generation antipsychotics 
(SGA) had over twice the rate of new incident cases of met-
abolic syndrome after three years, compared to those treated 
with first generation antipsychotic agents (27.8% vs. 9.8%) 
(73). In patients without metabolic syndrome at baseline, 
the risk of developing this combination of metabolic abnor-
malities was significantly greater in patients started on SGA 
(odds ratio 3.6). 
For the increased risk of MetS and other metabolic ab-
normalities in patients with schizophrenia, three comple-
mentary and partially overlapping causes are put forward in 
the literature: lifestyle factors, aspects of the psychotic disor-
der and antipsychotic medication. A number of recent stud-
ies explore the underlying genetic risk for the development 
of metabolic abnormalities (76,85,101). Future studies will 
need to address possible gene-environment interactions 
with specific antipsychotic agents (101).
People with schizophrenia on average have a lifestyle 
which increases their risk for the development of MetS: 
sedentary lifestyle, lack of regular physical activity, poor 
food intake, substance use and high rates of smoking 
(25,38,39). Part of these lifestyle factors are influenced by 
aspects of the illness such as negative symptoms and vul-
nerability to stress. Older studies have showed an increased 
liability for people with schizophrenia to develop metabol-
ic abnormalities in the absence of antipsychotic medica-
tion, and there are indications of an increased risk for dia-
betes in first-degree relatives (21,25,39). Also, some studies 
have showed increased visceral adiposity, elevated glycae-
mia and higher cortisol levels in first-episode patients be-
fore treatment (25,40,41). A recent study showed that peo-
ple with schizoaffective disorder have a higher vulnerabil-
ity to develop MetS compared to people with bipolar disor-
der or schizophrenia (99). 
The increased risk to develop MetS under antipsychotic 
agents is in part related to their propensity to induce weight 
gain. Although all antipsychotics can induce weight changes, 
the relative risk to induce clinically relevant weight changes 
(>7% increase) is clearly different between antipsychotic 
agents (25,29,31). In up to 25% of cases of MetS under an-
tipsychotic treatment, no weight gain or increased abdomi-
nal adiposity was present, suggesting a direct link between 
Table 3  Definitions of metabolic syndrome (45-48)
ATP III
(3 out of 5 criteria required)
ATP III A
(3 out of 5 criteria required)
IDF 
(waist plus 2 criteria required)
Waist (cm)
Blood pressure
HDL (mg/dl)
Triglycerides (≥150 mg/dl)
Glucose (mg/dl)
M >102, F >88
≥130/85*
M <40, F <50
≥150
≥110**
M >102, F >88
≥130/85*
M <40, F <50
≥150
≥100**
M ≥94, F ≥80
≥130/85*
M <40, F <50
≥150
≥100**
ATP – Adult Treatment Protocol; IDF – International Diabetes Federation
*or treated with antihypertensive medication; **or treated with insulin or hypoglycaemic medication.
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Table 4  Prevalence of metabolic syndrome (MetS) in people with schizophrenia
Study Country N Design Mean age % MetS Criteria
Heiskanen et al (78)
Almeras et al (62)
Basu et al (65)
Cohn et al (68)
Kato et al (80)
Straker et al (96)
Meyer et al (83)
McEvoy et al (82)
Saari et al (88)
Correll et al (69)
De Hert et al (71)
De Hert et al (72)
Hagg et al (77)
Lamberti et al (81)
Meyer et al (84)
Bobes et al (66)
Correll et al (70)
De Hert et al (73)
L’Italien et al (79)
Mulder et al (85)
Sicras-Mainar et al 
(94)
Srisurapanont et al 
(95)
Suvisaari et al (97)
Teixeira and Rocha 
(98)
Cerit et al (67)
De Hert et al (74)
De Hert et al (75)
Ellingrod et al (76)
Saddichha et al (90)
Schorr et al (91)
Schorr et al (92)
Schorr et al (93)
van Winkel et al (99)
Finland
Canada
Canada
USA
Canada
USA
USA
USA
USA
Finland
USA
Belgium
Belgium
Sweden
USA
USA
Spain
USA
Belgium
USA
Netherlands
Spain
Thailand
Finland
Brazil
Turkey
Belgium
Europe
USA
India
Netherlands
Netherlands
Netherlands
Belgium
35
42
45
33
240
48
89
1231
342
92
31
367
430
415
100
130
106
79
269
93
80
1452
294
208
23
31
25
54
25
50
155
267
373
380
112
742
57
38
44
108
122
122
108
108
2270
58
99
433
53
260
503
92
Olanzapine
Risperidone
Schizoaffective disorder
White males
White females
First episode (maximal duration 2 year illness)
Duration illness <10 years
Duration illness 10 to 20 years
Duration illness >20 years
Clozapine
Antipsychotic monotherapy 
3 months after start antipsychotics 
3 months after start amisulpride
3 months after start aripiprazole
3 months after start clozapine
3 months after start olanzapine
3 months after start quetiapine
3 months after start risperidone
Placebo trials, placebo endpoint
Placebo trials, aripiprazole endpoint
Active comparator trials, olanzapine endpoint
Active comparator trials, aripiprazole endpoint
Different diagnosis treated with antipsychotics
First episode, before treatment with FGA
First episode, 3 year FGA
First episode, before treatment with SGA
First episode, 3 year SGA
First episode after treatment
Schizophrenia
Schizoaffective disorder
44.5
31.7
28.4
44.5
42.7
40.3
39.8
42.8
39.8
44.2
31.0
42.9
36.5
37.7
25.7
29.0
39.0
49.8
46.0
34.4
49.0
40.7
43.6
33.7
33.7
33.7
33.7
33.7
33.7
33.7
41.4
40.7
37.7
37.6
36.0
55.1
37.5
53.7
44.3
34.6
23.1
26.8
21.9
25.1
41.0
36.3
26.1
38.0
35.0
28.0
34.8
40.7
37.1
33.0
11.0
42.4
44.6
63.0
29.2
35.8
40.9
56.2
19.4
37.3
32.3
33.3
17.0
28.5
42.4
49.4
34.6
53.8
51.2
24.6
34.3
27.9
13.0
9.7
56.0
33.3
32.0
24.0
25.8
19.9
41.6
27.9
25.0
27.0
35.0
36.2
31.8
34.0
5.7
13.1
5.6
31.6
33.9
40.0
18.2
34.0
45.0
35.0
28.8
50.0
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III-A
IDF
IDF
IDF
IDF
IDF
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III
ATP III
ATP III
ATP III
ATP III
ATP III
IDF
ATP III
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
IDF
ATP III
ATP III
ATP III
ATP III-A
ATP III-A
FGA – first-generation antipsychotic; SGA – second generation antipsychotic; ATP - Adult Treatment Panel; IDF - International Diabets Federation
the antipsychotic agent and the development of metabolic 
abnormalities (25). Some authors link the receptor profile 
of antipsychotics to their differential liability to induce 
weight gain and other metabolic changes (25,29,33,41). An-
tagonism for muscarinergic receptors could lead to more 
pronounced weight gain. Antipsychotics can lead to in-
creased appetite by interfering with the dopamine reward 
system (32). There is emerging data that glucose abnormali-
ties can occur soon after initiation of treatment and that 
these can be reversible after discontinuation of medication, 
indicating a direct effect on pancreatic function (25,38, 
39,42).
Growing evidence suggests that children and adolescents 
who take antipsychotic medication are at higher risk of 
weight gain and metabolic effects than adults who use the 
same drugs (102-104).
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Guidelines for screeninG and MonitorinG 
Prevention should be key. Clinicians should take into ac-
count both the present CVD risk as well as the metabolic 
risk profile of the antipsychotic chosen. To avoid weight 
gain, diet and lifestyle interventions should be started early 
after treatment initiation.
Despite the risks, many patients with SMI have limited 
access to general healthcare, with less opportunity for car-
diovascular risk screening and prevention than would be 
expected in a non-psychiatric population (7,25-27). There is 
a lack of consensus over who should take responsibility for 
the general healthcare needs of mental health patients, which 
has resulted in a continuing failure to provide appropriate 
services. General health care needs in this population are 
commonly neglected and psychiatrists mainly focus on effi-
cacy of treatment of psychotic symptoms.
Over recent years, both national and international groups 
have developed screening and monitoring guidelines 
(14,105-112), but these have not made their way to routine 
clinical care for patients (113,114).
Before start of treatment, the cardio-metabolic risk profile 
of a patient should be assessed. At the start of treatment, 
patients should be closely monitored for the relevant meta-
bolic parameters. An easy screening tool for MetS is the 
measurement of waist circumference in combination with 
fasting glucose (sensitivity 100%) (96).
Lifestyle interventions, with diet, increased physical activ-
ity and smoking cessation, are the first-line treatments to de-
crease the risk for CVD in people with MetS (8). The Adult 
Treatment Panel guidelines recommend a reduced intake of 
saturated fat and cholesterol, increased intake of fibres and 
increased physical activity (46). A reduction of 10% of cho-
lesterol levels results in a 30% reduction of CVD risk. A low-
ering of blood pressure of 4 to 6% decreases CVD risk 15%. 
Smoking cessation would result in a 50 to 70% lowering of 
CVD prevalence. Maintaining a body mass index below 25 
lowers CVD risk 35 to 55%, and having active lifestyle (20 
minutes brisk walk a day) results in a similar decrease of risk 
(8). These data also apply for people with severe mental ill-
ness, but no studies are available that confirm that short-term 
beneficial effects of lifestyle interventions result in long-term 
Table 5  Incidence of metabolic syndrome (MetS) in people with schizophrenia
Study Country N Design Mean age % MetS Criteria
De Hert et al (71)
Attux et al (64)
De Hert et al (73)
L’Italien et al (79)
Saddichha et al (89)
Srisurapanont et al (95)
De Hert et al (74)
Meyer et al (84)
Schorr et al (93)
Belgium
Brazil
Belgium
USA
India
Thailand
Belgium
USA
Netherlands
31
44
155
16
16
20
45
21
37
91
151
212
198
30
35
122
108
8
10
12
34
24
20
164
147
143
77
129
260
Baseline aripiprazole
Endpoint aripiprazole
First episode 6 months
After 3 months SGA
After 3 months amisulpride
After 3 months aripiprazole
After 3 months clozapine
After 3 months olanzapine
After 3 months quetiapine
After 3 months risperidone
Placebo trials, placebo
Placebo trials, aripiprazole
Active comparator trials, olanzapine
Active comparator trials, aripiprazole
First episode 6 weeks
Naturalistic 1 year follow-up
First episode, 3 year FGA
First episode, 3 year SGA
First episode, 3 year amisulpride
First episode, 3 year aripiprazole
First episode, 3 year clozapine
First episode, 3 year olanzapine
First episode, 3 year quetiapine
First episode, 3 year risperidone
Baseline olanzapine
After 3 months olanzapine
Baseline risperidone
After 3 months risperidone
Baseline quetiapine
After 3 months quetiapine
Baseline ziprasidone
After 3 months ziprasidone
Baseline perphenazine
After 3 months perphenazine
12 months incidence
12 months reversibility
36.7
36.7
26.3
33.7
33.7
33.7
33.7
33.7
33.7
33.7
41.4
40.7
37.7
37.6
26.9
34.7
26.8
25.1
25.1
25.1
25.1
25.1
25.1
25.1
40.9
40.9
40.9
40.9
40.9
40.9
40.9
40.9
40.9
40.9
41.0
37.0
61.3
29.0
6.8
18.7
6.3
0.0
45.0
24.4
19.1
10.8
14.3
5.3
27.4
15.7
27.5
20.0
9.8
27.8
12.5
0.0
50.0
41.3
12.6
10.2
34.8
43.9
30.6
30.6
37.8
37.1
37.7
29.9
37.2
38.0
14.0
33.0
ATP III-A
ATP III-A
ATP III
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III
ATP III
ATP III
ATP III
IDF
IDF
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III-A
ATP III
ATP III
FGA – first-generation antipsychotic; SGA – second generation antipsychotic; ATP - Adult Treatment Panel; IDF - International Diabets Federation
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changes (115,116). However, there is growing evidence that 
lifestyle interventions can be effective for groups of patients 
with schizophrenia.
There is a general consensus that physical activity has a 
mild to moderate favorable effect on many metabolic and 
cardiovascular risk factors that constitute or are related to 
the MetS (117). Regular physical activity is effective in pre-
vention and treatment of hypertension (118,119), obesity 
(120), impaired glucose tolerance and diabetes (121) and 
dyslipidaemia (122). Therefore, it should be an important 
component in multidisciplinary programs for people with 
schizophrenia. At the moment, identifying an optimal dose 
or intervention strategy for physical activity programs in 
people who have schizophrenia is not possible (123). The 
current guidelines for the general population of accumulat-
ing 30 min of moderate lifestyle physical activity, five days a 
week (124) should also be applied to people who have schiz-
ophrenia. Compliance with these guidelines appears to 
markedly decrease the likelihood of MetS especially in high 
risk groups (117). In physical activity related treatment pro-
grams for people who have schizophrenia, special attention 
could be given to the specific cardio-metabolic comorbidi-
ties by using the physical activity recommendations 
for chronic somatic diseases (125). A physical activity pro-
gram should be adapted to the patients’ previous experi-
ences, their attitude towards physical activity, their personal 
preferences and objectives. 
If a patient develops metabolic abnormalities (e.g., weight 
gain, increased blood pressure, glucose or lipid levels) fol-
lowing initiation of antipsychotic therapy, consideration 
should be given to switching the patients to an SGA which 
has not been associated with significant weight gain or dia-
betes. Initiation of appropriate blood pressure, glucose or 
lipid lowering therapy should also be considered, in consul-
tation with the patient’s general practitioner when that is 
possible, or with a specialist physician when this is consid-
ered appropriate. Until recently, there was no data on the 
safety and efficacy of statins in patients also exposed to an-
tipsychotics. In patients with schizophrenia, statins were an 
effective and safe treatment for severe dyslipidaemia but 
they did not succeed in reversing MetS (126, 127).
A European current update of screening and monitoring 
guidance is being produced (128,129) and an update of the 
ADA/APA 2004 consensus document is expected to be pub-
lished this year (14).
conclusions
MetS and other CVD risk factors are highly prevalent in 
people with SMI. The psychiatrist needs to be aware of the 
potential metabolic side effects of antipsychotic medication 
and to include them in the risk/benefit assessment when 
choosing a specific antipsychotic. He should also be respon-
sible for the implementation of the necessary screening as-
sessments and referral for treatment of any physical illness. 
Multidisciplinary assessment of psychiatric and medical 
conditions is needed. Psychiatric treatment facilities should 
offer and promote healthy lifestyle interventions. The so-
matic treatments offered to people with severe and enduring 
mental illness should be at par with general health care in 
the non-psychiatrically ill population.
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